

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 106 183 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
12.09.2001 Bulletin 2001/37(51) Int Cl.⁷: C12N 15/13, C07K 16/32,
A61K 39/395, C12N 5/20,
G01N 33/577, G01N 33/68(43) Date of publication A2:
13.06.2001 Bulletin 2001/24

(21) Application number: 01101031.1

(22) Date of filing: 09.10.1997

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SEDesignated Extension States:
AL LT LV RO SI

(30) Priority: 18.10.1996 US 731794

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
97912708.1 / 0 931 147

(71) Applicants:

• Genentech, Inc.
South San Francisco, CA 94080-4990 (US)• BOARD OF REGENTS
UNIVERSITY OF TEXAS SYSTEM
Austin, TX 78701-2981 (US)(72) Inventor: Fendly, Brian M.
Half Moon Bay, CA 94019 (US)(74) Representative: Cripps, Joanna Elizabeth et al
Mewburn Ellis
York House
23 Kingsway
London WC2B 6HP (GB)

(54) Antibodies to erbB2 and their therapeutic uses

(57) Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.




FIG. 2



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 10 1031

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D, Y	B. FENDLY ET AL.: "Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/Neu gene product." CANCER RESEARCH, vol. 50, no. 5, 1 March 1990 (1990-03-01), pages 1550-1558, XP002055531 BALTIMORE, MD, USA * abstract * * figures * * table I * ---	1-3, 9	C12N15/13 C07K16/32 A61K39/395 C12N5/20 G01N33/577 G01N33/68
Y	EP 0 505 148 A (YEDA RESEARCH AND DEVELOPMENT COMPANY LTD.) 23 September 1992 (1992-09-23) * page 3, line 25 - line 26 * * claim 16 * ---	1-3, 9	
Y	M. SLIWOWSKI ET AL.: "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 37, March 1996 (1996-03), pages 625-626, XP002055533 USA * the whole document * ---	1, 2, 4, 6, 7, 9	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07K
Y	WO 96 32480 A (AMGEN INC.) 17 October 1996 (1996-10-17) * page 12, line 8 - line 12 * * claim 12 * ---	1, 2, 4, 6, 7, 9 -/-	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	19 July 2001	Nooitj, F	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	& : member of the same patent family, corresponding document		



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 01 10 1031

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)						
A	G. DIGIESI ET AL.: "Production and characterization of murine mAbs to the extracellular domain of human Neu oncogene product GP185HER2." HYBRIDOMA, vol. 11, no. 4, August 1992 (1992-08), pages 519-527, XP002028488 NEW YORK, NY, USA * abstract * * table I * * figure 4 * * page 525, line 17 - line 22 *	1,4,5,9							
A	Y. KITA ET AL.: "ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 226, no. 1, 4 September 1996 (1996-09-04), pages 59-69, XP002027856 DULUTH, MN, USA * page 68, line 1 - line 16 * * page 68, line 32 - line 36 *	1,9							
A	A. ILGEN ET AL.: "Characterization of anti-HER2 monoclonal antibodies which inhibit the growth of breast cancer cell lines in vitro." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 37, March 1996 (1996-03), page 84 XP002055530 USA see abstract 564 ---- -/-	1,9							
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>19 July 2001</td> <td>Nooij, F</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	19 July 2001	Nooij, F
Place of search	Date of completion of the search	Examiner							
THE HAGUE	19 July 2001	Nooij, F							



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 10 1031

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)
D,A	WO 89 06692 A (GENENTECH, INC.) 27 July 1989 (1989-07-27) * claims 16,22 * * page 30, line 28 - page 36, line 12 *	1,2,4,5, 9	
P,X	WO 97 20858 A (AMGEN, INC.) 12 June 1997 (1997-06-12) * page 10, line 14 - line 36 * * page 11, line 26 - line 28 *	1-7,9	
TECHNICAL FIELDS SEARCHED (Int.Cl.)			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	19 July 2001	Nooij, F	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document	

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 1031

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-07-2001

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 505148	A	23-09-1992	AU 1298392 A CA 2063239 A FI 921133 A JP 7224089 A MX 9201173 A NO 921040 A NZ 242000 A ZA 9201944 A		24-09-1992 18-09-1992 18-09-1992 22-08-1995 30-10-1992 18-09-1992 25-03-1994 25-11-1992
WO 9632480	A	17-10-1996	US 5783404 A AU 5448196 A		21-07-1998 30-10-1996
WO 8906692	A	27-07-1989	JP 11335297 A JP 11255666 A JP 3502885 T US 6165464 A US 5677171 A US 5720937 A US 5772997 A US 5725856 A US 5770195 A US 5720954 A		07-12-1999 21-09-1999 04-07-1991 26-12-2000 14-10-1997 24-02-1998 30-06-1998 10-03-1998 23-06-1998 24-02-1998
WO 9720858	A	12-06-1997	US 5783186 A AU 723492 B AU 1278497 A CA 2236913 A EP 0865448 A		21-07-1998 31-08-2000 27-06-1997 12-06-1997 23-09-1998